Evidence map›Paper›PMID 40715268›Full record

ArticleScientific reports2025

Adverse event reports of seizure for insomnia medication from 1967 to 2023.

Tae Hyeon Kim, Kyeongmin Lee, Jiyoung Hwang, Suhyun Lee, Hyesu Jo, Hanseul Cho, Hayeon Lee, Hye Jeong Baek, Jiseung Kang, Christa J Nehs and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tae Hyeon Kim *Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
Kyeongmin Lee *Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, South Korea.
Jiyoung Hwang *Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, South Korea.
Suhyun LeeDepartment of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, South Korea.
Hyesu JoCenter for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, South Korea.
Hanseul ChoCenter for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, South Korea.
Hayeon LeeCenter for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, South Korea.
Hye Jeong BaekDepartment of Regulatory Science, Graduate School, Kyung Hee University, Seoul, South Korea.
Jiseung KangSchool of Health and Environmental Science, College of Health Science, Korea University, Seoul, South Korea.
Christa J NehsDivision of Sleep Medicine, Harvard Medical School, Boston, MA, USA.
Guillaume FondCEReSS-Health Service Research and Quality of Life Center, Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, Marseille, France.
Laurent BoyerCEReSS-Health Service Research and Quality of Life Center, Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, Marseille, France.
Eun Kyoung ChungDepartment of Regulatory Science, Graduate School, Kyung Hee University, Seoul, South Korea. cekchung@khu.ac.kr.
Dong Keon YonDepartment of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea. yonkkang@gmail.com.

Funding

Ministry of Food and Drug Safety No. 21153MFDS601-1National Research Foundation of Korea RS-2024-00460379The Korea Institute of Drug Safety and Risk Management No. 20240417839-00
6 · The paper itself

Abstract

Insomnia may negatively impact seizure control; however, the corresponding evidence remains limited. This study analyzed the seizure risk associated with various insomnia medications using a comprehensive pharmacovigilance database and identified safe options for patients at high risk of seizures. VigiBase, a database of adverse drug reaction reports from over 140 countries, comprises 35 million reports published from 1967 to 2023. Medications for insomnia include benzodiazepines, Z-drugs, antidepressants, atypical antipsychotics, first-generation H1 antagonists, orexin receptor agonists, melatonin, and melatonin receptor agonists. We assessed the association between insomnia medications and seizure risk by analyzing the reported odds ratio (ROR) with 95% confidence intervals (CI) and the information component (IC) with IC

Indexed as

Hypnotics and SedativesSeizuresSleep Initiation and Maintenance DisordersAdultAdverse Drug Reaction Reporting SystemsAntidepressive AgentsAntipsychotic AgentsBenzodiazepinesDatabases, FactualFemaleHumansMaleMiddle AgedPharmacovigilanceAntidepressive AgentsAntipsychotic AgentsBenzodiazepinesHypnotics and SedativesInsomniaPharmacovigilanceSeizureWorld Health Organization

Identifiers

PMID40715268
PMCPMC12297222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.